Contact Us | |
"The Voice of Oncology in Massachusetts"
Delve into our disease-specific links, providing targeted insights to navigate the intricacies of various oncology and hematology diseases.
B
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
ARTICLE(S):
- Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations
LOCAL EXPERT: Andrew A. Lane, MD, PhD; Physician; Director, Blastic Plasmacytoid Dendritic Cell Neoplasm Center, DFCI; Associate Professor of Medicine, Harvard Medical School
VIDEO(S):
- Dr. Lane on Identification of BPDCN
- Dr. Lane on BPDCN treatment
- Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future PotentialRESOURCES:
Breast Cancer (ER+/HER2- metastatic)
RESOURCES:
G
Graft-vs-host disease (GVHD)
RESOURCES:
- GVHD Host: www.gvhdnow.com -- Contains HCP and patient education
VIDEO(S):
- GVHD Grading & Staging -- Zachariah DeFilipp, MD, MGH; Corey Cutler, MD, DFCI
- Acute Graft-Vs-Host Disease: Risk Factors -- Yi-Bin A. Chen, MD, MGH; Zachariah DeFilipp, MD, MGH
- Closing the Treatment Gap in Acute and Chronic GVHD: Post-HCT Innovative Targeted Approaches; Zachariah DeFilipp, MD, MGH
M
Multiple Myeloma
ARTICLE(S):
- Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
RESOURCES:
- Myeloma Central for patients & caregivers: www.myelomacentral.com/livingwithmm
- MM Center for Nurses for HCPs: www.mmcenterfornurses.com
- Standing in the Gaap for African American patients & caregivers: www.myelomacentral.com/africanamericans
- Multiple Myeloma Research Foundation
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
ARTICLE(S):
- Exploring REBLOZYL: A Breakthrough Therapy for Anemia in MDS
RESOURCES:
- National Cancer Institute information on MDS/MPN- MPN Connect -- Explore the insights and experiences from experts in the field of MPN
S
Systemic Mastocytosis (SM)
Systemic Mastocytosis (SM) is a clonal mast cell neoplasm associated with the uncontrolled proliferation and activation of abnormal mast cells. The World Health Organization (WHO) diagnostic criteria identify types of SM, including Indolent Systemic Mastocytosis (ISM) and Advanced Systemic Mastocytosis (AdvSM). SM is driven by the KIT D816V mutation in 95% of cases. Unpredictable and potentially severe symptoms occur in patients with SM. Read more about SM symptoms here.
It is critical to use high-sensitivity KIT D816V assays, as low-sensitivity assays may fail to detect the mutation. A highly sensitive PCR-based method can be used to screen for the presence of KIT D816V in peripheral blood. Read more about high-sensitivity KIT D816V testing here.
For more information on Systemic Mastocytosis, The Mast Cell Disease Society has additional resources here.
VIDEO(S):
-Treatment Options for Systemic Mastocytosis
-Avapritinib: Mechanism of Action
Massachusetts Society of Clinical Oncologists ©2024 |
